Durable responses with first-line platinum-based chemotherapy for advanced-stage urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 became the first phase III trial to establish a significant overall survival benefit from a combined chemoimmunotherapy approach in this disease setting. Herein, we discuss key findings from CheckMate 901 and their implications in the context of a rapidly evolving treatment landscape.

中文翻译：

---

晚期尿路上皮癌的联合治疗策略：范式转变

一线铂类化疗对晚期尿路上皮癌的持久缓解很少见，而且患者预后较差。最近，CheckMate 901 成为第一个 III 期试验，证明联合化学免疫治疗方法在这种疾病中具有显着的总体生存获益。在此，我们讨论 CheckMate 901 的主要发现及其在快速发展的治疗环境中的影响。